Welcome to our dedicated page for ICON PLC news (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on ICON PLC stock.
ICON plc (NASDAQ: ICLR) is a clinical research organisation headquartered in Dublin, Ireland, operating in the research and development in biotechnology industry. This news page focuses on company announcements and updates that relate to its clinical research activities, financial performance and corporate developments.
ICON’s news releases commonly cover quarterly financial results, including revenue, net income, adjusted EBITDA and related non‑GAAP measures. These updates often discuss business wins, book‑to‑bill ratios, cash generation and capital allocation decisions such as share repurchase activity, as reflected in the company’s second and third quarter 2025 results announcements.
Investors and industry observers can also find news about ICON’s participation in investor and healthcare conferences. The company regularly announces presentations at events such as global healthcare conferences and growth stock conferences, as well as the scheduling of earnings conference calls and webcasts. These items provide insight into how ICON communicates its strategy and performance to the market.
Corporate governance and leadership changes are another key news category. For example, ICON has announced a CEO transition, detailing succession planning and board decisions. The company also publishes the results of its annual general meeting, including shareholder votes on director elections, auditor ratification and share authorisations.
In addition, ICON highlights recognition of its clinical research capabilities, such as independent benchmarking reports that assess its performance in phase 1 clinical trials. News may also include updates on specific research programmes, such as vaccine study updates noted in its filings. For ongoing visibility into ICON plc’s operations, financial reporting and role as a clinical research organisation, this news feed aggregates company-issued information in one place.
ICON plc (NASDAQ: ICLR) reported strong Q2 2022 results with net business wins of $2,323 million and a book-to-bill ratio of 1.20. Revenue reached $1,935.2 million, up 122.1% year-over-year. Adjusted EBITDA stood at $354.3 million, 18.3% of revenue, reflecting a yearly increase of 120.2%. Adjusted net income was $235.8 million, with earnings per share of $2.86. The company revised its full year 2022 revenue guidance to $7,690 - $7,810 million, anticipating a 40.3% to 42.5% increase year-over-year.
ICON, a leading healthcare intelligence and clinical research organization (NASDAQ: ICLR), will release its financial results for Q2 2022 on July 27, 2022, after market close. A conference call to discuss these results is scheduled for July 28, 2022, at 8:00am ET. This announcement underscores ICON's dedication to transparency and investor communication. As of March 31, 2022, ICON employed approximately 39,300 individuals across 138 locations globally, emphasizing its expansive operational capacity.
ICON plc (NASDAQ: ICLR) announced that CFO Brendan Brennan will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 7:00 AM ET. Additionally, CEO Steve Cutler is set to present at the Jefferies Healthcare Conference on June 9, 2022, at 2:00 PM ET, with live webcasts available. As of March 31, 2022, ICON employed approximately 39,300 employees across 138 locations in 53 countries, providing outsourced services in clinical research to various sectors. For updates, visit the Investor section on ICON's website.
ICON plc (NASDAQ: ICLR), a leading healthcare intelligence and clinical research organization, announced that CFO Brendan Brennan will present at the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 5:20 PM PT. The presentation details will be available on their Investor Relations website, under the 'Events' section. ICON, headquartered in Dublin, Ireland, employs approximately 39,300 staff across 138 locations in 53 countries, providing services to various health organizations.
ICON plc (NASDAQ: ICLR) reported a robust first quarter for 2022, achieving record net business wins of $2,426 million and a book to bill ratio of 1.28. Revenue increased by 121.6% year on year to $1,902 million, with adjusted EBITDA growing 124.5% to $340.6 million. The company maintained a closing backlog of $19.6 billion and reaffirmed full-year revenue guidance of $7,770 - $8,050 million. Notably, a $300 million early repayment was made on Term Loan B, reducing net debt to $4.58 billion.
ICON plc (NASDAQ:ICLR), a leader in healthcare intelligence and clinical research, will host a live webcast of its Analyst Day on March 17, 2022, at 12:30 PM ET in Blue Bell, Philadelphia. The event will feature presentations from ICON's executive team and will conclude around 3:30 PM ET, followed by a Q&A session. Updates and links to the webcast will be available in the Investor section of ICON's website.
ICON, headquartered in Dublin, employs approximately 38,330 people across 142 locations globally, offering outsourced services to various organizations.
ICON plc (NASDAQ:ICLR) reported remarkable financial results for Q4 and the full year 2021. The company achieved record net business wins of $2,378 million in Q4, elevating the full-year total to $6,958 million, with a book to bill ratio of 1.27. Q4 adjusted revenue surged 147.4% year-over-year to $1,881.1 million, and the full-year revenue rose by 95.9% to $5,480.8 million. Adjusted EBITDA reached $332.5 million for Q4 and $970.0 million for the full year. The company reaffirmed its revenue guidance for 2022, projecting growth between 41.8% and 46.9%.
ICON plc (NASDAQ: ICLR), a leading clinical research organization, announced that CFO Brendan Brennan will present at the Citi Healthcare Conference on February 24, 2022, at 11:45 AM ET. This event will provide valuable insights into ICON's operations and contributions to healthcare research. For updates, including live webcast links, visit the Investor section of ICON's website under 'Events.' Headquartered in Dublin, Ireland, ICON employs approximately 37,960 staff across 159 locations in 53 countries, focusing on advancing clinical research from molecule to medicine.
ICON plc (NASDAQ: ICLR) forecasts full-year 2022 revenue between
ICON plc (NASDAQ: ICLR) announced that CEO Dr. Steve Cutler will present at the 40th Annual JP Morgan Healthcare Conference on January 12, 2022, at 07:30 AM ET. This conference is a significant event in the healthcare sector where industry leaders share insights. ICON, headquartered in Dublin, Ireland, employs approximately 37,960 staff globally and focuses on advancing clinical research. The company provides outsourced services to various organizations, emphasizing innovations in drug development and patient care. For updates and live webcasts, visit the Investor section on ICON's website.
FAQ
What is the current stock price of ICON PLC (ICLR)?
What is the market cap of ICON PLC (ICLR)?
